HIV-associated Kaposi sarcoma (KS) is commonly staged using the AIDS Clinical Trials Group criteria, which classify 3 variables— tumor extent (T), immune status (I), and systemic symptoms (S)—into good risk (0) and poor risk (1). Although validated in the United States and Europe, these criteria have not been systematically evaluated in sub-Saharan Africa, where the burden of KS is greatest.
We reviewed medical charts of adult patients with HIV-associated KS seen at the Uganda Cancer Institute from 1992 to 2007. Vital status at 2 years after KS diagnosis was determined from the medical chart, or by contacting the patient or next of kin. Survival estimates used Kaplan–Meier methods. Predictors were evaluated for 2 periods: 0–4 months and 4–24 months after diagnosis.
At 2 years after diagnosis, 167 (41%) patients were alive, 156 (39%) had died, and 81 (20%) were lost to follow-up. The Kaplan–Meier estimate of 2-year survival was 57%. S1 was associated with death in months 0–4 [hazard ratio: 6.4, 95% confidence interval: 1.9–21.1], whereas T1 was associated with death in months 4–24 [hazard ratio: 4.0, 95% confidence interval: 1.4 to 11.5]. Immune status was not associated with survival.
Systemic symptoms were strongly associated with death in the early period after KS diagnosis, whereas tumor status was most predictive of death in the 4- to 24-month period. These findings suggest that different processes may influence outcomes in early and late periods following KS diagnosis. Further studies are needed to confirm these observations and to identify better predictors of KS survival in sub-Saharan Africa.
Supplemental Digital Content is Available in the Text.
*Uganda Cancer Institute, Kampala, Uganda;
†Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda;
‡Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Departments of §Medicine;
¶Global Health, University of Washington, Seattle, WA.
Correspondence to: Warren Phipps, MD, MPH, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M1-B140, Seattle, WA 98109 (e-mail: firstname.lastname@example.org).
Supported by the National Institutes of Health/National Cancer Institute: K23 CA 150931, U54 CA190146.
Presented in part at the International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies; November 7–8, 2011; Bethesda, MD, and ASCO Annual Meeting; May 29, 2015–June 2, 2015; Chicago, IL.
The authors have no conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).
Received August 02, 2016
Accepted November 28, 2016